Trials on Celltech's asthma drug halted
Saturday 26 April 2003
Development work on one of Celltech's most exciting new drugs has been abandoned after trials revealed serious side effects.
The biotech group's new treatment for asthma and other lung diseases caused one patient to suffer a swollen bowel earlier this week, and the US regulatory authorities advising shutting the testing programme down. Merck, the US pharmaceuticals giant which has been conducting the trials, and which would have paid royalties to Celltech if the drug ever reached the market, decided to scrap the development work, and Celltech's shares dipped 6 per cent to 280p.
Peter Allen, Celltech's finance director, described Merck's decision as "a bolt from the blue". He said: "We are very disappointed. They are being very cautious but it is their right to choose."
It was not clear yesterday why the drug, known as a PDE-4 inhibitor, should cause colitis, but similar drugs being developed by other pharmaceuticals groups do not appear to have caused the side effect.
Merck is continuing its asthma collaboration with Celltech and is likely to take a different PDE-4 inhibitor into human trials. Mr Allen said: "They have put a huge amount of resource behind the collaboration and we see this more as a delay than anything else."
The Merck-supported drug was one of only five Celltech drugs being trialled on humans and the project was valued by some analysts at up to £100m.
- 1 Alan Rickman admits editing 'terrible' script with friends in Pizza Hut behind backs of writers on Robin Hood: Prince of Thieves
- 2 Rarest Beanie Baby of them all could be sold for £62,500 on eBay
- 3 Professional big game hunter Ian Gibson crushed to death by elephant during hunt
- 4 Farmer told to tear down mock-Tudor castle after hiding construction behind hay bales
- 5 Rebecca Francis accuses Ricky Gervais of using 'influence' to target female hunters after receiving barrage of death threats
Yemen crisis: Meet the child soldiers who have forsaken books for Kalashnikovs
Alan Rickman admits editing 'terrible' script with friends in Pizza Hut behind backs of writers on Robin Hood: Prince of Thieves
Rarest Beanie Baby of them all could be sold for £62,500 on eBay
Professional big game hunter Ian Gibson crushed to death by elephant during hunt
Farmer told to tear down mock-Tudor castle after hiding construction behind hay bales
If I’m being racially abused I don’t need a stranger with a saviour complex to rescue me
The only black face in the Ukip manifesto is on the page about overseas aid
Ukip is the only main political party to not address LGBT rights in its manifesto
Food banks: One million Britons will soon be using them, according to Trussell Trust
Religion isn't growing, it is becoming vigorous in its demise, says philosopher AC Grayling
BBC election debate: The one photo that summed up the whole 90-minute leaders debate
iJobs Money & Business
£20000 - £25000 per annum + OTE £45,000: SThree: SThree Group have been well e...
£50000 - £667000 per annum + excellent benefits : Ashdown Group: IT Manager / ...
£13000 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...
£40000 - £45000 per annum + benefits : Ashdown Group: Training Programme Manag...